Sign in to view content

Abicipar for nAMD Provides Faster Retinal Fluid Resolution, and Achieved Similar Dryness Through Week 104 With Fewer Injections

Nancy M. Holekamp, MD, FASRS

Video
Published 2020

Related

Abicipar Phase 2 MAPLE Trial: Evaluation of All Patients With Post-Injection Inflammation
Tarek S. Hassan, MD, FASRS
Annual Meeting Talks
2020
Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER
Carl D. Regillo, MD
Annual Meeting Talks
2020
High-dose Aflibercept Therapy in nAMD and DME Eyes With Suboptimal Response to Standard Dose of Anti-VEGF Therapy: A Retrospective Analysis
Jared S. Nielsen, MD, MBA
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more